Analysts expect the New York-based company to report quarterly earnings at 68 cents per share, down from 82 cents per share ...

Pfizer (PFE) prepares to report its first-quarter earnings on April 29, and analysts have adopted a cautious stance on the pharmaceutical giant’s stock. Analysts’ expectations have been tempered by ...

Fintel reports that on April 8, 2025, Goldman Sachs downgraded their outlook for Pfizer (NYSE:PFE) from Buy to Neutral. Analyst Price Forecast Suggests 39.12% Upside As of April 1, 2025 ...

Goldman Sachs downgraded Pfizer (PFE) to Neutral from Buy with a price target of $25, down from $32, after assuming coverage of the name. The firm says that on the back of a challenging past two ...

BMY), Pfizer (NYSE:PFE), and AbbVie (NYSE:ABBV). Eli Lilly (LLY) has ended a three-day selloff after Goldman Sachs analyst Asad Haider upgraded the Indiana-based drugmaker to Buy from Neutral ...

On this episode of Stock Movers: - Goldman Sachs (GS) shares are higher after ... maintaining her $225 price target. - Pfizer (PFE) is down today as it plans to abandon its obesity pill ...

In today’s CEO Daily: Diane Brady talks to Pfizer CEO Albert Bourla about defending science amid a backdrop of political ...

Pharmaceutical giant Pfizer (PFE) has been through a rough spot in 2025, joining the rest of the stock market as President Donald Trump’s trade ...

Fintel reports that on April 8, 2025, Goldman Sachs downgraded their outlook for Pfizer (SNSE:PFE) from Buy to Neutral. There are 4,005 funds or institutions reporting positions in Pfizer.

Fintel reports that on April 8, 2025, Goldman Sachs downgraded their outlook for Pfizer (SNSE:PFECL) from Buy to Neutral. There are 4,005 funds or institutions reporting positions in Pfizer.